Trial Profile
Phase II trial of carboplatin and pemetrexed plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Apr 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 Planned End Date changed from 1 May 2017 to 1 May 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 May 2016 to 1 May 2019.